source
- TRexBio raises $117 million in IPO as Retension secures $45 million Nasdaq debut for hypertension therapyTRexBio completed its initial public offering on Thursday, pricing the shares at a level that generated about $116.7 million in gross proceeds. The funding will support the company’s development of…
- TRex Bio prices $117M IPO to fund Treg-targeted immune therapiesTRex Bio announced pricing of its initial public offering at $117 million, selling 8,333,334 shares at $14 each, meeting the low end of its earlier guidance. The company will begin trading on Nasd…